European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe
AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.
You may also be interested in...
2013’s Most Notable Stories In “The Pink Sheet” DAILY
FDA budget challenges, biosimilars, R&D revamps and social media are among stories from the past year that captured the attention of readers and reflect major biopharma trends.
European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers
Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.
European Notebook: A Smooth Succession At Roche, EMA’s New Leadership Team, A Medicine Bank In Greece, Atorvastatin Price Drop In Ireland
Lufthansa's Christoph Franz will become Roche’s chairman next year; more restructuring details emerge from the European Medicines Agency; pharma companies donate medicines in Greece; Ireland names preferred medicines and aims to cut atorvastatin price.